IGF2BP3 and breast carcinoma: Interestingly, we found that the positivity rate of IGF2BP3 in breast cancer without axillary lymph node metastasis (18.6%, 29/156) was significantly higher than that in patients with axillary lymph node metastasis (3.5%, 5/143) (P<0.001).